20 Sep 2021
As the world continues to grapple with the health implications of COVID-19, unintended consequences were inevitable. In this data-led story, we look at the effect the pandemic has had on global plastic wastage and what policymakers can do to tackle the issue.
The coronavirus pandemic has not helped plastic wastage
Demand for biomedical plastics has surged during the pandemic.1 Syringes, surgical gowns, COVID-19 test kits, latex gloves, shoe covers, sanitizer containers, visors, disposable blades and scalpels, disposable masks; the list goes on. If we had a plastic wastage problem before, the coronavirus pandemic has not helped.
The facts are startling and the size and scale eye-watering. Here are few highlights:
Even more worryingly, surgical items include resilient materials like polypropylene, polyurethane, polyacrylonitrile and polyethylene that can remain in the environment for up to 450 years.7
450 years
Time for a surgical mask to fully decompose
Substantial volumes of plastic waste are not being collected, sorted, recycled or safely disposed of.
Plastics accumulating in terrestrial and aquatic ecosystems can be harmful
On some parts of the earth, more than 1 million pieces of microplastic have been identified per square mile8, and millions of tonnes are being washed into the sea. But we know plastics accumulating in terrestrial and aquatic ecosystems can be harmful.
With no change to the way we use and manage plastic (see Figure 1, Business as usual), around 30 million tonnes of plastic pollution will be entering aquatic ecosystems each year by 2040, with another 55 million tonnes entering terrestrial ecosytems.
Biomass- and algae-based polymers could replace some petroleum-based materials, reflected in the reduce and substitute and system change scenarios shown in Figure 1.
Figure 1: The future of plastics - potential pathways from multiple Monte Carlo simulations (Mt/y)
Figure 2: Impacting the plastic waste chain
"China banned imports of plastic waste in 2017 and Turkey has followed this year, with new restrictions due to come into effect in July. This is a significant change, because Turkey received almost half of all global packaging waste exports in early 2021. We need to work much harder to reduce and manage our own waste"
Sora Utzinger, Senior ESG Analyst
"Companies we invest in warn of a recycling crisis. We want to see companies do more to reduce virgin plastic use, increase recycled content, design for reusability, and report quantitively on their progress in these areas"
Eugenie Mathieu, Senior ESG Analyst
"There are useful new applications developed during the pandemic that could deliver compound growth and reduce waste. They include double-chamber, pre-filled syringes for freeze-dried vaccines, which should help distribution issues and increase the shelf life of the drugs. We are also interested in the multiple uses for UV as a disinfectant. Light within specific wavelengths, known as UV-C, can disinfect airflows and surfaces. This is being used in light fittings, reducing the risk of infection from airborne bacteria and viruses, as well as to clean re-usable masks"
Matt Kirby, Portfolio Manager
The negative impact that long-lived plastics have on the environment is evident everywhere.
Steps can be taken immediately to address the problem
Steps can be taken immediately by various stakeholders to address the problem:
As Steve Waygood, chief responsible investment officer at Aviva Investors, puts it: “Humankind has made around 8,300 million metric tons of virgin plastic, and the compounds take centuries to degrade. Our enthusiasm for the product has made a stamp on the planet that will be visible for millennia. Our water, soil and oceans are all affected: we need action.”
References
Important information
Except where stated as otherwise, the source of all information is Aviva Investors Global Services Limited (AIGSL). Unless stated otherwise any views and opinions are those of Aviva Investors. They should not be viewed as indicating any guarantee of return from an investment managed by Aviva Investors nor as advice of any nature. Information contained herein has been obtained from sources believed to be reliable but has not been independently verified by Aviva Investors and is not guaranteed to be accurate. Past performance is not a guide to the future. The value of an investment and any income from it may go down as well as up and the investor may not get back the original amount invested. Nothing in this material, including any references to specific securities, assets classes and financial markets is intended to or should be construed as advice or recommendations of any nature. This material is not a recommendation to sell or purchase any investment.
In Europe this document is issued by Aviva Investors Luxembourg S.A. Registered Office: 2 rue du Fort Bourbon, 1st Floor, 1249 Luxembourg. Supervised by Commission de Surveillance du Secteur Financier. An Aviva company. In the UK Issued by Aviva Investors Global Services Limited. Registered in England No. 1151805. Registered Office: St Helens, 1 Undershaft, London EC3P 3DQ. Authorised and regulated by the Financial Conduct Authority. Firm Reference No. 119178. In France, Aviva Investors France is a portfolio management company approved by the French Authority “Autorité des Marchés Financiers”, under n° GP 97-114, a limited liability company with Board of Directors and Supervisory Board, having a share capital of 17 793 700 euros, whose registered office is located at 14 rue Roquépine, 75008 Paris and registered in the Paris Company Register under n° 335 133 229. In Switzerland, this document is issued by Aviva Investors Schweiz GmbH.
In Singapore, this material is being circulated by way of an arrangement with Aviva Investors Asia Pte. Limited (AIAPL) for distribution to institutional investors only. Please note that AIAPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIAPL in respect of any matters arising from, or in connection with, this material. AIAPL, a company incorporated under the laws of Singapore with registration number 200813519W, holds a valid Capital Markets Services Licence to carry out fund management activities issued under the Securities and Futures Act (Singapore Statute Cap. 289) and Asian Exempt Financial Adviser for the purposes of the Financial Advisers Act (Singapore Statute Cap.110). Registered Office: 1 Raffles Quay, #27-13 South Tower, Singapore 048583. In Australia, this material is being circulated by way of an arrangement with Aviva Investors Pacific Pty Ltd (AIPPL) for distribution to wholesale investors only. Please note that AIPPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIPPL in respect of any matters arising from, or in connection with, this material. AIPPL, a company incorporated under the laws of Australia with Australian Business No. 87 153 200 278 and Australian Company No. 153 200 278, holds an Australian Financial Services License (AFSL 411458) issued by the Australian Securities and Investments Commission. Business Address: Level 30, Collins Place, 35 Collins Street, Melbourne, Vic 3000, Australia.
The name “Aviva Investors” as used in this material refers to the global organization of affiliated asset management businesses operating under the Aviva Investors name. Each Aviva investors’ affiliate is a subsidiary of Aviva plc, a publicly- traded multi-national financial services company headquartered in the United Kingdom. Aviva Investors Canada, Inc. (“AIC”) is located in Toronto and is registered with the Ontario Securities Commission (“OSC”) as a Portfolio Manager, an Exempt Market Dealer, and a Commodity Trading Manager. Aviva Investors Americas LLC is a federally registered investment advisor with the U.S. Securities and Exchange Commission. Aviva Investors Americas is also a commodity trading advisor (“CTA”) registered with the Commodity Futures Trading Commission (“CFTC”) and is a member of the National Futures Association (“NFA”). AIA’s Form ADV Part 2A, which provides background information about the firm and its business practices, is available upon written request to: Compliance Department, 225 West Wacker Drive, Suite 2250, Chicago, IL 60606.